Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Melanoma Clinical Trial

Official title:

Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05280314
• Other study ID #: IO102-IO103-032/IOB-032
• Secondary ID: MK-3475-E40
• Status: Recruiting
• Phase: Phase 2
• Start date: December 21, 2023
• Est. completion date: January 2027

Study information

• Verified date: March 2024
• Source: IO Biotech
• Contact: Diane McDowell SVP, Clinical Development and Medical Affairs, MD
• Phone: +1 267 252 7296
• Email: dmd[@]iobiotech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.

Description:

This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. Approximately 60 patients with melanoma or SCCHN will be included (approximately 15 for each indication).During the neoadjuvant period, patients in cohort A, cohort B and Cohort C (Arm A) will receive IO102-IO103 and pembrolizumab KEYTRUDA® Q3W. Patients in Cohort C (Arm B) will receive pembrolizumab KEYTRUDA® Patients with melanoma will receive 3 doses of neoadjuvant treatment. Patients with SCCHN will receive 2 or 3 doses of neoadjuvant treatment, at the investigator's discretion. Surgical resection will be performed 1 to 3 weeks after the last dose of neoadjuvant treatment. All patients in cohort A,B and Cohort C (Arm A)will receive post-surgery treatment with IO102-IO103 and pembrolizumab KEYTRUDA® for a total of 15 cycles (up to 45 weeks). Patients in Cohort C (Arm B) will receive post-surgery treatment with pembrolizumab KEYTRUDA® for a total of 15 cycles (up to 45 weeks). Patients with melanoma and patients with SCCHN who do not require SOC RT ± cisplatin will start post-surgery treatment after adequate recovery from surgery (approximately 1 to 2 months; no more than 12 weeks).Patients with SCCHN who require postoperative SOC therapy after surgery will start post-surgery IO102-IO103 and pembrolizumab KEYTRUDA® after adequate recovery from SOC therapy (approximately 1 to 2 months; no more than 12 weeks). Objective response will be based on imaging; pathologic tumor response of the surgical specimens will be assessed at the time of surgery. Safety will be assessed by recording adverse events. The primary endpoint will be the percentage of patients with major pathologic response (MPR) in the resected tumor tissue after neoadjuvant treatment. Secondary endpoints include disease-free survival (DFS) at 2 years after surgery. All patients will have an end-of-treatment visit approximately 4 weeks after their last dose of trial treatment. Follow-up visits will be conducted at 6 and 12 months after the end-of-treatment visit. Following completion of the 12-month follow-up period, long-term follow-up for overall survival (OS) will be conducted every 6 months for at least a further 12 month.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: January 2027
• Est. primary completion date: April 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Melanoma-specific inclusion criteria:

• Histologically or cytologically confirmed diagnosis of cutaneous stage III melanoma according to the American Joint Committee on Cancer (AJCC) 8th edition. Patients with resectable tumors are eligible for this trial either at presentation for primary melanoma with concurrent regional nodal metastasis or at the time of clinically

detected nodal recurrence; they may belong to any of the following groups:

• Primary cutaneous melanoma with clinically apparent regional lymph node metastases
• Clinically detected recurrent melanoma at the proximal regional lymph node(s) basin
• Clinically detected primary cutaneous melanoma involving multiple regional nodal groups
• Clinically detected nodal melanoma (if single site) arising from an unknown primary
• Relapsed resectable stage III melanoma

SCCHN-specific inclusion criteria:

• Stage III or IVA resectable locoregionally advanced SCCHN of the oral cavity, oropharynx (with known HPV-negative or p16-negative status assessed per institution standard or centrally), hypopharynx, or larynx. Inclusion criteria applicable across cohorts: In addition to the indication-specific inclusion criteria, a patient must meet all the

following general criteria to be eligible for participation in this trial:

1. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1

2. Candidate for surgical resection with curative intent

3. The patient (or legally acceptable representative if applicable) provides written informed consent for the trial.

4. Age =18 years on the day of signing the informed consent form

5. Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides.

6. Eastern Cooperative Oncology Group (ECOG) performance score status of 0 or 1

7. Adequate organ function as defined below performed on screening labs obtained within 4

weeks before first dose:

• Absolute neutrophil count (ANC) =1500/µL
• Platelets =100 000/µL
• Hemoglobin =9.0 g/dL or =5.6 mmol/L (Note: Criterion must be met without packed red blood cell transfusion within the prior 2 weeks. Patients can be on stable dose of erythropoietin [= approximately 3 months].)
• Creatinine or measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine or creatinine clearance) =1.5 × upper limit of normal (ULN) or =30 mL/min for patient with creatinine levels >1.5 × institutional ULN
• Serum total bilirubin =1.5 × ULN or direct bilirubin = ULN for patients with total bilirubin levels >1.5 × ULN
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 × ULN
• International normalized ratio (INR) or prothrombin time (PT) =1.5 × ULN unless the patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within the therapeutic range of intended use of anticoagulants
• Activated partial thromboplastin time (aPTT) =1.5 × ULN unless the patient is receiving anticoagulant therapy as long as PT or PTT is within the therapeutic range of intended use of anticoagulants

8. Women of childbearing potential: Negative urine or serum pregnancy within 72 hours prior to receiving the first dose of trial medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

9. Women of childbearing potential: Willing to use highly effective contraception or abstain from heterosexual activity for the duration of the trial and for at least 120 days after the last dose of trial medication

10. HIV-infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease defined as: a Patients on ART must have a CD4+ T-cell count >350 cells/mm3 at time of screening b Patients on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to first dose of trial medication (Day 1) c Patients on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to first dose of trial medication (Day 1) 11. Patients who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to start of trial intervention. Note: Patients should remain on anti-viral therapy throughout trial intervention and follow local guidelines for HBV anti-viral therapy after completion of trial intervention.

Hepatitis B screening tests are not required unless:

• Known history of HBV infection
• Mandated by local health authority. 12. Patients with a history of hepatitis C (HCV) infection are eligible if HCV viral load is undetectable at screening. Note: Patients must have completed curative antiviral therapy at least 4 weeks prior to start of trial intervention.

Hepatitis C screening tests are not required unless:

• Known history of HCV infection
• Mandated by local health authority.

Melanoma-specific exclusion criteria:

• Current or prior history of uveal, mucosal, or acral melanoma
• Oligometastatic stage IV melanoma
• History of in-transit metastases within the last 6 months
• Prior therapy targeting BRAF and/or MEK

SCCHN-specific exclusion criteria:

• Nasopharyngeal cancer, unknown primary, nasal cavity or paranasal sinus carcinoma Exclusion criteria applicable across cohorts:

In addition, patients meeting any of the following criteria must be excluded:

1. Currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks of the first dose of trial treatment Note: Patients who have entered the follow-up phase of an investigational trial may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.

2. Any prior treatment for the tumor under study

3. Prior therapy for another tumor with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137), and discontinued from that treatment due to a grade 3 or higher immune-related adverse event (irAE)

4. Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of trial treatment

• Note: Patients must have recovered from all adverse events (AEs) due to previous therapies (i.e., grade =1 at baseline). Patients with grade =2 neuropathy are eligible for the trial. Patients with endocrine-related AEs grade =2 requiring treatment or hormone replacement are also eligible.
• Note: If the patient has had major surgery, the patient must have recovered adequately from the procedure and/or complications from the surgery prior to starting trial treatment.

5. Live or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Note: Administration of inactivated vaccines, mRNA-based vaccines [e.g., COVID-19] and vector-based vaccines are allowed.

6. Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Patients who are currently receiving steroids at a dose equivalent to <5 mg/day of prednisone do not need to discontinue steroids prior to enrollment. Patients who require topical, ophthalmologic and inhalational steroids will not be excluded from the trial. Patients with hypothyroidism stable on hormone replacement or Sjögren's syndrome will not be excluded from the trial.

7. Additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.

8. History of an allogeneic tissue/solid organ transplant.

9. Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Patients with type I diabetes mellitus; hypothyroidism only requiring hormone replacement; skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment; or conditions not expected to recur in the absence of an external trigger are permitted to enroll.

10. History of radiation pneumonitis

11. History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

12. Active infection requiring systemic therapy

13. HIV-infected patients with a history of Kaposi sarcoma and/or Multicentric Castleman Disease

14. Has known active hepatitis B virus (HBV; defined as hepatitis B surface antigen [HBsAg] reactive and/or detectable HBV DNA) or known active hepatitis C virus (HCV) (defined as anti HCV Ab positive and detectable HCV ribonucleic acid [RNA] [qualitative]) infection. Note: Testing for hepatitis B and hepatitis C is not required unless

1. Known history of HBV or HCV infection

2. Mandated by local health authority. Patients with a history of hepatitis will be screened using serology to confirm status.

15. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator

16. Psychiatric or substance abuse disorders that would interfere with the patient's ability to cooperate with the trial requirements

17. Severe hypersensitivity (grade =3) to pembrolizumab and/or any of its excipients

Related Conditions & MeSH terms

• Melanoma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• IO102-IO103
IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
• Pembrolizumab KEYTRUDA®
Pembrolizumab KEYTRUDA® administered intravenously

Locations

Country	Name	City	State
Australia	Peter MacCallum Cancer Centre	Melbourne	Victoria
Australia	Melanoma Institute Australia The Uiniversity of Sydney, and Royal North Shore Hospital	Sydney	New South Wales
Denmark	Aarhus University Hospital	Aarhus
Denmark	Copenhagen University Hospital Herlev	Copenhagen
France	CHRU Lille	Lille
France	Hôpital Ambroise-Paré	Paris
France	Institut Gustave Roussy	Paris
Germany	Universitätsklinikum Essen & Research Alliance Ruhr	Essen
Germany	Universität Heidelberg, Medizinische Fakultät	Heidelberg
Spain	Hospital Universitario Quirón Dexeus	Barcelona
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Hospital Clínico Universitario de Valencia -INCLIVA	Valencia
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Yale	New Haven	Connecticut
United States	Massey Cancer Center	Richmond	Virginia

Sponsors (4)

Lead Sponsor	Collaborator
IO Biotech	Almac, Merck Sharp & Dohme LLC, Theradex

Countries where clinical trial is conducted

United States,  Australia,  Denmark,  France,  Germany,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major pathologic response	Major pathologic response, defined as pathologic complete response (pCR) (0% residual viable tumor) or near pCR (=10% residual viable tumor)	Observed in the resected tumor tissue after neoadjuvant treatment at surgery
Secondary	Pathologic complete response	Pathologic complete response (pCR) (0% residual viable tumor)	Observed in the resected tumor tissue after neoadjuvant treatment at surgery
Secondary	Pathologic tumor response	Pathologic tumor response (= 49% residual viable tumor) at surgery	Pathologic tumor response of the surgical specimens will be assessed at the time of surgery.
Secondary	Objective response rate	Objective response rate (ORR), determined by RECIST 1.1	Determined after 9 weeks of treatment
Secondary	Disease-free survival	Disease-free survival (DFS) from the date of surgery	at 2 years after surgery
Secondary	Event-free survival	Event-free-survival (EFS)	Determined after 9 weeks of treatment
Secondary	Event-free survival	Event-free-survival (EFS)	at 2 years after surgery